DK1094834T3 - Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf - Google Patents

Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf

Info

Publication number
DK1094834T3
DK1094834T3 DK99930089T DK99930089T DK1094834T3 DK 1094834 T3 DK1094834 T3 DK 1094834T3 DK 99930089 T DK99930089 T DK 99930089T DK 99930089 T DK99930089 T DK 99930089T DK 1094834 T3 DK1094834 T3 DK 1094834T3
Authority
DK
Denmark
Prior art keywords
treatment
bowel syndrome
irritable bowel
pharmaceutical composition
sepsis
Prior art date
Application number
DK99930089T
Other languages
English (en)
Inventor
Suad Efendic
Per Hellstroem
Original Assignee
Melacure Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melacure Therapeutics Ab filed Critical Melacure Therapeutics Ab
Application granted granted Critical
Publication of DK1094834T3 publication Critical patent/DK1094834T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK99930089T 1998-06-11 1999-06-08 Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf DK1094834T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (1)

Publication Number Publication Date
DK1094834T3 true DK1094834T3 (da) 2004-01-05

Family

ID=20411665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99930089T DK1094834T3 (da) 1998-06-11 1999-06-08 Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf

Country Status (19)

Country Link
US (1) US6348447B1 (da)
EP (2) EP1405642A1 (da)
JP (2) JP2002517468A (da)
AT (1) ATE252912T1 (da)
AU (1) AU738994B2 (da)
CA (1) CA2321700C (da)
CZ (1) CZ300873B6 (da)
DE (1) DE69912434T2 (da)
DK (1) DK1094834T3 (da)
ES (1) ES2205845T3 (da)
HU (1) HUP0103147A3 (da)
NO (1) NO327738B1 (da)
NZ (1) NZ506163A (da)
PL (1) PL198802B1 (da)
PT (1) PT1094834E (da)
RU (1) RU2226402C2 (da)
SE (1) SE9802080D0 (da)
WO (1) WO1999064060A1 (da)
ZA (1) ZA200004080B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1267912A2 (en) 2000-03-14 2003-01-02 Burkhard Göke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
DE60134403D1 (de) * 2000-05-19 2008-07-24 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp-1
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
WO2003072195A2 (en) 2002-02-20 2003-09-04 Eli Lilly And Company Method for administering glp-1 molecules
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
EP2368909A1 (en) 2003-06-12 2011-09-28 Eli Lilly and Company GLP-1 analog fusion proteins
EP2210612B1 (en) 2003-06-18 2016-10-05 Ocera Therapeutics, Inc. Macrocyclic antagonists of the motilin receptor
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
DK1791542T3 (da) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte til lægemiddel-levering
WO2006111169A1 (en) * 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
BRPI0609676A2 (pt) 2005-05-13 2011-10-18 Lilly Co Eli composto de glp-1 peguilado,e, uso do mesmo
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
ES2531159T3 (es) * 2005-07-29 2015-03-11 Solasia Pharma K K Compuestos y métodos para el tratamiento del cáncer
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
US20100137204A1 (en) * 2006-12-29 2010-06-03 Zheng Xin Dong Glp-1 pharmaceutical compositions
US8236760B2 (en) * 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
BRPI0818874A2 (pt) * 2007-10-24 2015-05-05 Mannkind Corp Liberação de agentes ativos
CA2703338A1 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2727147A1 (en) 2008-06-17 2009-12-23 Otsuka Chemical Co., Ltd. Glycosylated glp-1 peptide
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
EP2427204B1 (en) 2009-05-06 2017-04-05 Janssen Biotech, Inc. Melanocortin receptor binding conjugates
KR20200028501A (ko) 2009-06-12 2020-03-16 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011013728A1 (ja) * 2009-07-29 2011-02-03 第一三共株式会社 経粘膜吸収性を付与したモチリン類似ペプチド化合物
RU2012122162A (ru) 2009-10-30 2013-12-10 Глитек,Инк. Гликолизированная форма аналога антигенного glp-1
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104203221A (zh) 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
DK2875043T3 (da) 2012-07-23 2017-03-27 Zealand Pharma As Glucagonanaloger
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
DK3057984T3 (da) 2013-10-17 2018-10-08 Zealand Pharma As Acylerede glucagon-analoger
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
ES2833099T3 (es) 2015-02-11 2021-06-14 Gmax Biopharm Llc Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
RU2753193C2 (ru) 2016-12-09 2021-08-12 Зилэнд Фарма А/С Ацилированные двойные агонисты glp-1/glp-2
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides

Also Published As

Publication number Publication date
NO20006194L (no) 2001-01-25
NZ506163A (en) 2004-10-29
CZ300873B6 (cs) 2009-09-02
NO327738B1 (no) 2009-09-14
SE9802080D0 (sv) 1998-06-11
JP2002517468A (ja) 2002-06-18
HUP0103147A3 (en) 2002-02-28
AU738994B2 (en) 2001-10-04
WO1999064060A1 (en) 1999-12-16
PT1094834E (pt) 2004-03-31
AU4669799A (en) 1999-12-30
PL343104A1 (en) 2001-07-30
CA2321700C (en) 2011-05-03
ES2205845T3 (es) 2004-05-01
PL198802B1 (pl) 2008-07-31
JP2010270125A (ja) 2010-12-02
ATE252912T1 (de) 2003-11-15
EP1094834B1 (en) 2003-10-29
EP1405642A1 (en) 2004-04-07
HUP0103147A2 (hu) 2002-01-28
NO20006194D0 (no) 2000-12-06
CA2321700A1 (en) 1999-12-16
ZA200004080B (en) 2001-12-24
US6348447B1 (en) 2002-02-19
CZ20004491A3 (en) 2001-05-16
EP1094834A1 (en) 2001-05-02
DE69912434T2 (de) 2004-05-06
RU2226402C2 (ru) 2004-04-10
DE69912434D1 (de) 2003-12-04

Similar Documents

Publication Publication Date Title
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
RU2000133249A (ru) Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
NO984005L (no) Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
EP1992641A3 (en) GLP-1 analogues
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
WO2000034331A3 (en) Analogues of glp-1
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
WO2003061362A3 (en) Methods and compositions for treating polycystic ovary syndrome
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
LU90025I2 (fr) Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R)
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
IS1966B (is) Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
SE9603725D0 (sv) New teatment
DE69011618D1 (de) Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
EP1359159A3 (en) Analogues of GLP-1
SE8501202D0 (sv) Human intestinal hormone and its use
SE8501203D0 (sv) Mammal intestinal hormone precursor and its use